{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:29:33Z","timestamp":1783103373539,"version":"3.54.6"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"NIH\/NCI","award":["R35CA197605"],"award-info":[{"award-number":["R35CA197605"]}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1136\/ijgc-2019-001103","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T13:09:30Z","timestamp":1591103370000},"page":"733-743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Differential blood count as triage tool in evaluation of pelvic masses"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8024-3066","authenticated-orcid":false,"given":"Daniel W","family":"Cramer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Benjamin IV","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison F","family":"Vitonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annekathryn","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2019-001103_bb0010","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2008.11.011","article-title":"Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands","volume":"112","author":"Vernooij","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2019-001103_bb0015","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1471-0528.1990.tb02448.x","article-title":"A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer","volume":"97","author":"Jacobs","year":"1990","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1136\/ijgc-2019-001103_bb0020","doi-asserted-by":"crossref","first-page":"82.e1","DOI":"10.1016\/j.ajog.2016.03.003","article-title":"Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses","volume":"215","author":"Coleman","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-2019-001103_bb0025","doi-asserted-by":"crossref","first-page":"228.e1","DOI":"10.1016\/j.ajog.2010.03.043","article-title":"Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass","volume":"203","author":"Moore","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-2019-001103_bb0030","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/AOG.0b013e31821b5118","article-title":"Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors","volume":"117","author":"Ueland","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2019-001103_bb0035","first-page":"815","article-title":"Diagnosis and management of adnexal masses","volume":"80","author":"Givens","year":"2009","journal-title":"Am Fam Physician"},{"key":"10.1136\/ijgc-2019-001103_bb0040","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00011-017-1026-6","article-title":"The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer","volume":"66","author":"Prodromidou","year":"2017","journal-title":"Inflamm Res"},{"key":"10.1136\/ijgc-2019-001103_bb0045","doi-asserted-by":"crossref","first-page":"8794","DOI":"10.1200\/JCO.2005.01.7632","article-title":"Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group","volume":"23","author":"Timmerman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2019-001103_bb0050","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9%3C2068::AID-CNCR25%3E3.0.CO;2-8","article-title":"Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women","volume":"85","author":"Jeyarajah","year":"1999","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2019-001103_bb0055","first-page":"489","article-title":"Factors influencing serum CA125II levels in healthy postmenopausal women","volume":"10","author":"Pauler","year":"2001","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1136\/ijgc-2019-001103_bb0060","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ygyno.2008.05.006","article-title":"The epidemiology of CA-125 in women without evidence of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial","volume":"110","author":"Johnson","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2019-001103_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-017-0315-6","article-title":"Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort","volume":"10","author":"Fortner","year":"2017","journal-title":"J Ovarian Res"},{"key":"10.1136\/ijgc-2019-001103_bb0070","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1158\/1055-9965.EPI-18-1120","article-title":"Predicting circulating CA125 levels among healthy premenopausal women","volume":"28","author":"Sasamoto","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1136\/ijgc-2019-001103_bb0075","first-page":"428","article-title":"CA 125 levels in menopausal women","volume":"76","author":"Westhoff","year":"1990","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2019-001103_bb0080","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ygyno.2010.08.028","article-title":"Correlates of the preoperative level of CA125 at presentation of ovarian cancer","volume":"119","author":"Cramer","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2019-001103_bb0085","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1001\/jama.1985.03360140090031","article-title":"Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality","volume":"254","author":"Grimm","year":"1985","journal-title":"JAMA"},{"key":"10.1136\/ijgc-2019-001103_bb0090","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1532-5415.1986.tb04906.x","article-title":"Absolute peripheral blood lymphocyte count and subsequent mortality of elderly men. The Baltimore longitudinal study of aging","volume":"34","author":"Bender","year":"1986","journal-title":"J Am Geriatr Soc"},{"key":"10.1136\/ijgc-2019-001103_bb0095","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.exger.2005.08.006","article-title":"Baseline total and specific differential white blood cell counts and 5-year all-cause mortality in community-dwelling older women","volume":"40","author":"Leng","year":"2005","journal-title":"Exp Gerontol"},{"key":"10.1136\/ijgc-2019-001103_bb0100","first-page":"5","article-title":"Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill","volume":"102","author":"Zahorec","year":"2001","journal-title":"Bratisl Lek Listy"},{"key":"10.1136\/ijgc-2019-001103_bb0105","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s12094-011-0687-9","article-title":"Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer","volume":"13","author":"Asher","year":"2011","journal-title":"Clin Transl Oncol"},{"key":"10.1136\/ijgc-2019-001103_bb0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00262-008-0516-3","article-title":"Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment","volume":"58","author":"Cho","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1136\/ijgc-2019-001103_bb0115","doi-asserted-by":"crossref","first-page":"9781","DOI":"10.7314\/APJCP.2014.15.22.9781","article-title":"May the platelet to lymphocyte ratio be a prognostic factor for epithelial ovarian cancer?","volume":"15","author":"Kokcu","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1136\/ijgc-2019-001103_bb0120","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3802\/jgo.2012.23.4.265","article-title":"Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer","volume":"23","author":"Raungkaewmanee","year":"2012","journal-title":"J Gynecol Oncol"},{"key":"10.1136\/ijgc-2019-001103_bb0125","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ygyno.2014.01.026","article-title":"Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer","volume":"132","author":"Williams","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2019-001103_bb0130","doi-asserted-by":"crossref","first-page":"8831","DOI":"10.1007\/s13277-015-3533-9","article-title":"Preoperative platelet\/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients","volume":"36","author":"Zhang","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1136\/ijgc-2019-001103_bb0135","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.7150\/jca.23606","article-title":"Diagnostic accuracy of inflammatory markers for distinguishing malignant and benign ovarian masses","volume":"9","author":"Eo","year":"2018","journal-title":"J Cancer"},{"key":"10.1136\/ijgc-2019-001103_bb0140","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejogrb.2007.05.012","article-title":"Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer","volume":"138","author":"Bishara","year":"2008","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1136\/ijgc-2019-001103_bb0145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0301-2115(96)02662-0","article-title":"Whole blood cell counts and leucocyte differentials in patients with benign or malignant ovarian tumours","volume":"72","author":"den Ouden","year":"1997","journal-title":"Eur J Obstet Gynecol Reprod Biol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24023405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24023405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2019-001103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:26:47Z","timestamp":1753234007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24023405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1048891X24023405"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2019-001103","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential blood count as triage tool in evaluation of pelvic masses","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2019-001103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}